Literature DB >> 8652981

[Long-term outcome of radiotherapy of choroid hemangioma].

H Schilling1, W Sauerwein, W Friedrichs, S Brylak, N Bornfeld, A Wessing.   

Abstract

The usual therapeutic approach to circumscribed choroidal hemangiomas of the posterior pole consists of scatter photocoagulation of the tumor surface. This may often require repetitive treatment or additional invasive measures prior to coagulation due to massive exudative detachment of the retina. In this study, external beam irradiation with high-energy photons (total absorbed dose: 20 Gy) was applied to 36 symptomatic patients. The indication for treatment was exudative retinal detachment including or threatening the fovea. The mean duration of follow-up was 4.5 years (4 months to 24 years, median 4 years). In 23 cases (63.8%) complete resolution of the subretinal fluid could be achieved; 13 cases (36.2%) showed residual serous detachment at some distance from the fovea. The visual acuity improved by two or more lines in 14 cases (38.9%), remained stable in 14 cases and decreased in only 8 cases (22.2%). The functional success was dependent on the interval between onset of first subjective symptoms and treatment. External beam irradiation is a successful form of treatment for choroidal hemangiomas.

Entities:  

Mesh:

Year:  1996        PMID: 8652981

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  3 in total

1.  [In Process Citation].

Authors: 
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

2.  [Outcome of radiotherapy of choroid hemangioma].

Authors:  T Wiegel
Journal:  Strahlenther Onkol       Date:  1997-06       Impact factor: 4.033

3.  [The photon therapy of subfoveal choroidal neovascularization in age-dependent macular degeneration. The results of a prospective study in 40 patients].

Authors:  U Prettenhofer; A Haas; R Mayer; A Oechs; B Pakisch; H Stranzl; P Willfurth; A Hackl
Journal:  Strahlenther Onkol       Date:  1998-12       Impact factor: 3.621

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.